Abstract: Method for the production of formula (I) lumateperone or its acid addition salts so that the enantiomer compound with stereochemistry 6bR,10aS is separated form the cis racemate using resolution and the formula (II) stereoisomer is alkylated with 4-halo-4?-fluoro butyrophenone (X?I, Br, Cl) to produce the formula (I) lumateperone, or optionally its acid addition salt. The object of the invention also relates to the amorphous form of the morphologically uniform p-toluenesulfonic acid salt of lumateperone and to the naphthalene-2-sulfonic acid salt of lumateperone, to the 1:2 stoichiometry salt of lumateperone formed with naphthalene-2-sulfonic acid.

Abstract: The invention relates to a robust and reproducible process for the preparation of polymorph form B of treprostinil diethanolamine salt, comprising the following steps: a. treprostinil is dissolved in methanol, b. to the solution of step a) diethanolamine or its methanol solution is added, c. the reaction mixture of step b) is agitated till dissolution, d. when salt formation is completed in step c), first portion of an aprotic solvent is added to the solution, e. the solution of step d) is filtered to remove insoluble impurities, f. the filtrate of step e) is seeded with polymorph form B of treprostinil diethanolamine salt, g. to the crystal suspension obtained in step f) a second portion of the aprotic solvent is added, h. the suspension of step g) is agitated until crystallisation is completed, i. the crystals are separated, washed and dried.

Abstract: A drive base module of a modularly constructed multifunctional handheld machine is configured to connect to at least one attachment device. The drive base module includes at least one connection device including at least one drive-technological interface and/or a data-technological interface configured to connect to the at least one attachment device. The drive base module further includes at least one drive unit configured to drive the at least one attachment device in a state in which the at least one attachment device is connected to the at least one connection device. The drive base module further includes at least one rechargeable battery unit; and at least one information output unit configured to output information to an operator acoustically and/or haptically.

Abstract: Novel 4,6-disubstituted aminopyrimidine derivatives with the following structure (I) have anti-HIV activity.

Abstract: Embodiments are directed towards generating applications that include multi-sized types running in managed code. During the compilation of an intermediate language version of an application, if a multi-size type is encountered, a runtime engine may perform actions to process the multi-size types. Accordingly, architecture information associated with the target computer may be determined. Data types corresponding to the architecture of the target computer and the multi-sized types may be determined based on the architecture information. Native code calls associated with an intermediate language code calls may be determined such that the parameters of the native code calls match the architecture dependent data types. And, a machine code version of the intermediate language code call may be generated. The generated machine code version of the intermediate language code may be executed with the data types specific to the target computer.

Abstract: The invention relates to normal or acidic salts of dasatinib and the hydrate and solvate forms thereof. More specifically the invention concerns: dasatinib cyclamic acid salt, dasatinib cyclamic acid (1:1) salt Form I, dasatinib cyclamic acid (1:1) salt Form II, dasatinib hydrogen bromide (1:2) salt, dasatinib methane sulfonic acid (1:2) salt, dasatinib p-toluenesulfonic acid (1:1) dihydrate salt, anhydrous dasatinib p-toluenesulfonic acid (1:1) salt Form I, anhydrous dasatinib p-toluenesulfonic acid (1:1) salt Form II, dasatinib p-toluenesulfonic acid (1:1) salt methanol solvate. Moreover the invention relates process for preparing dasatinib salts, pharmaceutical compositions comprising thereof and the use of dasatinib salts the treatment of cancer.

Abstract: The invention relates to an improved process for the preparation of pharmaceutical active ingredients and also to high purity salts and pharmaceutical compositions prepared by said process. More particularly the invention relates to an economical process for the preparation of the compound having the international non-proprietary name (INN) vortioxetine and the chemical nomenclature 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine. Vortioxetine corresponds to the following Formula Still more particularly the invention relates to the preparation of high purity vortioxetine L-(+)-mandelate salt of the Formula IX, the conversion of this salt into other highly pure salts and also to the formulation of said salts.

Abstract: Novel 4,6-disubstituted aminopyrimidine derivatives with the following structure (I) have anti-HIV activity.

Abstract: The invention relates to normal or acidic salts of dasatinib and the hydrate and solvate forms thereof. More specifically the invention concerns: dasatinib cyclamic acid salt, dasatinib cyclamic acid (1:1) salt Form I, dasatinib cyclamic acid (1:1) salt Form II, dasatinib hydrogen bromide (1:2) salt, dasatinib methane sulfonic acid (1:2) salt, dasatinib p-toluenesulfonic acid (1:1) dihydrate salt, anhydrous dasatinib p-toluenesulfonic acid (1:1) salt Form I, anhydrous dasatinib p-toluenesulfonic acid (1:1) salt Form II, dasatinib p-toluenesulfonic acid (1:1) salt methanol solvate. Moreover the invention relates process for preparing dasatinib salts, pharmaceutical compositions comprising thereof and the use of dasatinib salts the treatment of cancer.

Abstract: Embodiments are directed towards generating applications that include multi-sized types running in managed code. During the compilation of an intermediate language version of an application, if a multi-size type is encountered, a runtime engine may perform actions to process the multi-size types. Accordingly, architecture information associated with the target computer may be determined. Data types corresponding to the architecture of the target computer and the multi-sized types may be determined based on the architecture information. Native code calls associated with an intermediate language code calls may be determined such that the parameters of the native code calls match the architecture dependent data types. And, a machine code version of the intermediate language code call may be generated. The generated machine code version of the intermediate language code may be executed with the data types specific to the target computer.

Abstract: The invention relates to an improved process for the preparation of pharmaceutical active ingredients and also to high purity salts and pharmaceutical compositions prepared by said process. More particularly the invention relates to an economical process for the preparation of the compound having the international non-proprietary name (INN) vortioxetine and the chemical nomenclature 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine. Vortioxetine corresponds to the following Formula Still more particularly the invention relates to the preparation of high purity vortioxetine L-(+)-mandelate salt of the Formula IX, the conversion of this salt into other highly pure salts and also to the formulation of said salts.

Abstract: Novel 4,6-disubstituted aminopyrimidine derivatives with the following structure (I) have anti-HIV activity.

Abstract: Embodiments are directed towards generating applications that include multi-sized types running in managed code. During the compilation of an intermediate language version of an application, if a multi-size type is encountered, a runtime engine may perform actions to process the multi-size types. Accordingly, architecture information associated with the target computer may be determined. Data types corresponding to the architecture of the target computer and the multi-sized types may be determined based on the architecture information. Native code calls associated with an intermediate language code calls may be determined such that the parameters of the native code calls match the architecture dependent data types. And, a machine code version of the intermediate language code call may be generated. The generated machine code version of the intermediate language code may be executed with the data types specific to the target computer.

Abstract: The present invention relates to microRNA (miRNA) compounds for use in the treatment of consequences of acute ischemia/reperfusion, a method for preparing miRNA compounds by using test ischemic-reperfusion, test preconditioning and test postconditioning of biological samples, use of the miRNA compounds in the preparation of pharmaceutical compositions having cytoprotective and/or anti-ischemic effect in ischemic cardiac diseases.

Abstract: Embodiments are directed towards generating applications that include multi-sized types running in managed code. During the compilation of an intermediate language version of an application, if a multi-size type is encountered, a runtime engine may perform actions to process the multi-size types. Accordingly, architecture information associated with the target computer may be determined. Data types corresponding to the architecture of the target computer and the multi-sized types may be determined based on the architecture information. Native code calls associated with an intermediate language code calls may be determined such that the parameters of the native code calls match the architecture dependent data types. And, a machine code version of the intermediate language code call may be generated. The generated machine code version of the intermediate language code may be executed with the data types specific to the target computer.

Abstract: Embodiments are directed towards embodiments are directed towards managing parameter types for generic functions. During ahead-of-time (AOT) compilation of an application one or more generic functions may be encountered during compilation of the application. The AOT compiler may generate machine code for the encountered generic function. If parameter types associated with the encountered generic function are indefinite the AOT compiler may generate machine code that normalizes each parameter of the encountered generic function to conform to a shared version of the encountered generic function. Machine code may be generated for calling the shared version of the generic function with the normalized parameters. Machine code for calling the shared version of the generic function may be inserted and/or placed inside the machine code for the encountered generic function and inserted into a machine code version of the application.

Abstract: The present invention relates to 4-pyrimidinylamino-benzenesulfonamide derivatives of general formula (I) and pharmaceutically acceptable salts, solvates, hydrates, regioisomeric and polymorphic forms thereof, processes for manufacturing of them, the use of them, as well as pharmaceutical compositions containing at least one of them as pharmaceutically active agent(s) together with pharmaceutically acceptable carrier, excipient and/or diluents, especially for the inhibition of polo-like kinases (PLKs) and the treatment of cancer. Said 4-pyrimidinylamino-benzenesulfonamide compounds have been also identified as new drug candidates for the prevention and/or treatment of infectious diseases like bacterial diseases e.g. tuberculosis, including the currently multidrug-resistant tuberculosis (MDR-TB), extensively drug-resistant tuberculosis (XDR-TB) as well as for preventing tuberculosis.

Abstract: Embodiments are directed towards generating applications that include multi-sized types running in managed code. During the compilation of an intermediate language version of an application, if a multi-size type is encountered, a runtime engine may perform actions to process the multi-size types. Accordingly, architecture information associated with the target computer may be determined. Data types corresponding to the architecture of the target computer and the multi-sized types may be determined based on the architecture information. Native code calls associated with an intermediate language code calls may be determined such that the parameters of the native code calls match the architecture dependent data types. And, a machine code version of the intermediate language code call may be generated. The generated machine code version of the intermediate language code may be executed with the data types specific to the target computer.

Abstract: The invention relates to toxin peptides capable of selectively inhibiting a Kv1.3 potassium channel protein. The toxin peptides of the invention are modified anuroctonus scorpion toxin peptides.

Abstract: The invention relates compounds of general formula (I) and pharmaceutically acceptable salts and solvates thereof wherein R1 is halogen, vinylene-aryl, substituted aryl, heteroaryl or a benzo[1,3]dioxolil group, W is a group of formula —NH—SO2—R2 or heteroaryl group or NHR3 group where R3 is hydrogen or heteroaryl; and n is 1, 2, 3 or 4. Furthermore, the present invention is directed to pharmaceutical composition containing at least one compound of general formula (I) and/or pharmaceutically acceptable salts or solvates thereof and for the use of them for the preparation of pharmaceutical compositions for the prophylaxis and/or the treatment of protein kinase related, especially CDK9-related diseases e.g. cell proliferative disease, infectious disease, pain, cardiovascular disease and inflammation.